Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in … – Nasdaq
|
Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in …
Nasdaq "While early, these data highlight the potential for Genethon's micro-dystrophin gene therapy program and once again underscore the significance of dystrophin production in the treatment of DMD," said Douglas Ingram, Sarepta's president and chief … |
